Paolo Chesi

Outcomes of Platinum/Pemetrexed Rechallenge in Pleural Mesothelioma: The Role of Platinum-Free Interval in a Multicenter Real-World Analysis

Rajiv C. Shah, Martin Reck, Christian Grohé, Martin Faehling et autres

Background Real-world (rw) use of rechallenge with platinum/pemetrexed (PP) in pleural mesothelioma (PM) has been recommended in international guidelines, but evidence is scarce and based on few very small retrospective studies. Methods 612 patients with PM treated with first-line PP between 2010 …

de, it (code pays fourni par la source)

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study

Rajiv Shah, Eva L. Buchmeier, Hans‐Georg Kopp, Frank Griesinger et autres

BACKGROUND: There is currently no approval for second-line treatment in pleural mesothelioma (PM). Since the approval of nivolumab/ipilimumab, most guidelines recommend platinum/pemetrexed as subsequent treatment. However, the data supporting this sequence are primarily based on efficacy observed in the first-line setting, while …

de, it (code pays fourni par la source)

Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?

Francesca Romana Di Pietro, Rosa Maria Falcone, Sofia Verkhovskaia, Giulia Poti et autres

Background: IIID melanoma, its role in stage IIIA disease remains a matter of discussion. This subgroup is generally considered to be at lower risk of recurrence, whereas currently available treatments are associated with potential adverse events, some of which may be severe …

it (code pays fourni par la source)

Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series

Rosa Maria Falcone, Alessandra Frezzolini, Emanuele Bruni, Sofia Verkhovskaia et autres

Background: Immune checkpoint inhibitors (ICIs) are the gold standard therapy for cutaneous melanoma and are also used effectively in treating other types of skin cancer. Hematologic toxicities are rare, but potentially a serious and life-threatening side effect of ICIs. Clinical and biological …

it (code pays fourni par la source)

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

Rajiv C. Shah, Eva Lotte Buchmeier, Hans‐Georg Kopp, Daniel Christian Christoph et autres

BACKGROUND: Despite the approval of nivolumab/ipilimumab, the prognosis of patients with pleural mesothelioma (PM) remains poor. Although this combination has shown improved survival in the landmark CheckMate (CM)-743 trial, evidence from real-world settings remains limited. METHODS: In this retrospective, multicenter study, the …

de, it (code pays fourni par la source)

First-Line Nivolumab Plus Ipilimumab in Pleural Mesothelioma: Efficacy and Safety Data from the Real-World MesoNet Study

Rajiv C. Shah, Eva Lotte Buchmeier, Hans‐Georg Kopp, Daniel Christian Christoph et autres

de (code pays fourni par la source)

Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study

Sofia Verkhovskaia, Rosa Maria Falcone, Francesca Romana Di Pietro, Maria Luigia Carbone et autres

Background: When monotherapy with PD-1 inhibitors in metastatic melanoma fails, there are currently no standard second-line choices. In case of the unavailability of clinical trials, ipilimumab represents a possible alternative treatment. Methods: We collected data of 44 patients who received ipilimumab after …

it (code pays fourni par la source)

Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience

Francesca Romana Di Pietro, Daniele Marinelli, Sofia Verkhovskaia, Giulia Poti et autres

Immunotherapy with anti-PD-1 antibodies significantly improved the prognosis in advanced melanoma patients, but most of them develop primary or secondary resistance to the treatment. In this study, we evaluated efficacy and safety of a chemotherapy regimen with weekly carboplatin plus paclitaxel (wCP) …

it (code pays fourni par la source)

Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients

Francesca Romana Di Pietro, Sofia Verkhovskaia, Rosa Maria Falcone, Giulia Poti et autres

Background: Stage III surgically resected melanoma is a disease at high risk of recurrence. Immune checkpoint inhibitors (ICIs) and the target therapy with BRAF and MEK inhibitors significantly changed the outcome of patients with metastatic melanoma and several studies have also shown …

it (code pays fourni par la source)

Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting.

Rajiv C. Shah, Martin Reck, Christian Grohé, Daniel Christian Christoph et autres

8085 Background: The approval of nivolumab/ipilimumab (IO) has extended the first-line treatment options in unresectable pleural mesothelioma (PM). In the Checkmate 743 trial, first-line IO treatment resulted in similar survival benefit for both non-epithelioid (NE) and epithelioid (E) subtype with median survival …

de, it (code pays fourni par la source)

3MO Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE: A reservoir for intrinsic resistance to KRAS G12C inhibitors

Daniele Marinelli, Simona Pisegna, Maristella Giammaruco, Paolo Chesi et autres

it (code pays fourni par la source)